HER2 in gynecologic cancers: a Brazilian study
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is looking at whether HER2, a protein linked to some cancers, is found in different gynecologic tumors. It tests stored tumor tissue from women in Brazil to learn more about this marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had cervical, endometrial, ovarian, fallopian tube, vulvar, or vaginal cancer.
- You were 18 or older when the tumor sample was taken.
- Your cancer diagnosis was between January 2020 and March 2025.
- You have enough stored tumor tissue from the original surgery to be tested.
- You did not receive chemotherapy or other cancer drugs before the surgery or biopsy.
- You are willing to sign a consent form, or a waiver is allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
Hear when a new Gynaecological Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.